WuXi and PRA canceling joint venture in China

With WuXi PharmaTech concentrating on manufacturing and PRA Health Sciences ($PRAH) developing its own global strategy, the two companies have decided to split up their China-focused joint venture. Instead, they will have an alliance but will divide their operations in the country after more than two years of collaboration. Story

Suggested Articles

Teva will produce its new migraine drug at a plant in Israel and more news of note.

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, nominee for FDA commissioner.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.